A biomarker present in 20% of ER+/HER2− breast cancers has been identified, with potential to predict heightened sensitivity to CDK4/6 inhibitor drugs. The post Biomarker Discovery Could Improve Personalized Care in ER+ Breast Cancer appeared first on Inside Precision Medicine.
